Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary

Athersys, Inc. (Nasdaq: ATHX) announced financial results for Q2 2023, with $48.8K in revenue compared to $2.3M in Q2 2022. Research and development expenses decreased to $10.6M from $20.8M, and general and administrative expenses decreased to $2.3M from $5.2M. Net loss for Q2 2023 was $(12.9)M, compared to $(23.6)M in Q2 2022. Cash and cash equivalents were $1.8M as of June 30, 2023.

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem^® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.

Second Quarter 2023 and Recent Corporate and Operational Highlights:

• Nominated healthcare executive and strategy consultant Neema Mayhugh, Ph.D. to the Company’s Board of Directors
• Surpassed two-thirds patient enrollment in the MASTERS-2 clinical trial with MultiStem for ischemic stroke
• Completed Memorandum of Understanding with Healios to provide consulting support with PMDA to explore the feasibility of adding Japanese patients to MASTERS-2 trial
• Presented as a finalist for the Biomedical Advanced Research and Development Authority’s (BARDA) “Just Breathe” program for a proposed clinical trial with MultiStem for acute respiratory distress syndrome (ARDS) and other COVID-19 co-morbidities
• Initiated enrollment of cohort 3 in the MATRICS-1 clinical trial with MultiStem for trauma using 3-D bioreactor manufactured clinical product
• Raised $3.7 million through a registered direct offering with institutional investors
• Continued reducing expenses to conserve cash and heightened focus on execution of MASTERS-2 trial
• Maintained operating expenses below $2.5 million per month
• Participated in several industry conferences to build awareness of Athersys and share MultiStem clinical and manufacturing progress, including:
  • The American Society for Neural Therapy and Repair Annual Conference
  • Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
  • Pharma Manufacturing World Summit
  • Allogeneic Cell Therapies Summit
  • American Thoracic Society’s Respiratory Innovation Summit

Management Commentary

“The second quarter of 2023 was marked by improved execution on all fronts, from continuing to maintain low operating expenses to improved enrollment in our ongoing clinical trials, including the start of cohort 3 enrollment in our MATRICS-1 trauma trial following a positive DSMB review. We also implemented the MASTERS-2 protocol changes agreed upon with the U.S. FDA in more than 60% of our trial sites with the remainder expected to be completed by the end of August. These protocol modifications now reflect the full potential benefit of MultiStem for patients with acute, moderate-to-severe ischemic stroke as well as the evolving standard of care. In addition, the FDA approved our request to conduct an unblinded interim analysis to evaluate whether the study size is sufficiently powered to achieve statistical significance. We look forward to sharing these results in early October,” said Daniel Camardo, Chief Executive Officer of Athersys.

Second Quarter Results

There was $48.8 thousand of revenue for the second quarter of 2023 compared with $2.3 million for the second quarter of 2022, which included the delivery of services under the arrangement with Healios. As of September 30, 2022, services under this arrangement were largely complete and were limited to close-out activities.

Research and development expenses were $10.6 million for the second quarter of 2023 compared with $20.8 million for the comparable period in 2022. The decrease reflects our restructuring plan which resulted in reduced clinical trial expenses which includes personnel, manufacturing, and other costs.

General and administrative expenses were $2.3 million for the second quarter of 2023 compared with $5.2 million for the comparable period in 2022, with the decrease primarily due to the restructuring.

Net loss for the second quarter of 2023 was $(12.9) million, or $(0.62) per share, compared with a net loss of $(23.6) million, or $(2.28) per share, for the comparable period in 2022.

Cash and cash equivalents were $1.8 million as of June 30, 2023, compared with $9.0 million as of December 31, 2022.

About MultiStem^®

MultiStem^® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem^® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, expected timetable for any results of our trials or analyses, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. In addition, a number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risk that we will be unable to raise capital to fund our operations in the near term and long term, including our ability to obtain funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, on terms acceptable to us or at all, and to continue as a going concern. The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations in the near term and long term, including our ability to obtain funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, on terms acceptable to us or at all, and to continue as a going concern; whether we receive a grant from BARDA; our collaborators’ ability and willingness to continue to fulfill their obligations under the terms of our collaboration agreements and generate sales related to our technologies; the possibility of unfavorable results from ongoing and additional clinical trials involving MultiStem; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in an early stage clinical trial may not be predictive of results in later stage or large scale clinical trials; our ability to successfully license our SIFU technology; our ability to regain and maintain compliance with the Nasdaq continued listing requirements; the timing and nature of results from MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial evaluating the administration of MultiStem for the treatment of ischemic stroke; our ability to meet milestones and earn royalties under our collaboration agreements, including the success of our collaboration with Healios; the success of our MACOVIA clinical trial evaluating the administration of MultiStem for the treatment of ARDS induced by COVID-19 and other pathogens, and the MATRICS-1 clinical trial being conducted with The University of Texas Health Science Center at Houston evaluating the treatment of patients with serious traumatic injuries; the availability of product sufficient to meet our clinical needs and potential commercial demand following any approval; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials of our product candidates; the possibility of delays, work stoppages or interruptions in manufacturing by third parties or us, such as due to material supply constraints, contamination, operational restrictions due to COVID-19 or other public health emergencies, labor constraints, regulatory issues or other factors that could negatively impact our trials and the trials of our collaborators; uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem cell therapy for neurological, inflammatory and immune, cardiovascular and other critical care indications; changes in external market factors; changes in our industry’s overall performance; changes in our business strategy; our ability to protect and defend our intellectual property and related business operations, including the successful prosecution of our patent applications and enforcement of our patent rights, and operate our business in an environment of rapid technology and intellectual property development; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; the success of our efforts to enter into new strategic partnerships and advance our programs; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; the success of our competitors and the emergence of new competitors; and the risks mentioned elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022 under Item 1A, “Risk Factors” and our other filings with the SEC. You should not place undue reliance on forward-looking statements, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

(Tables follow)

Athersys, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
		June 30, 2023				December 31, 2022
		(Unaudited)				(Note)
Assets
Cash and cash equivalents		$	1,803			$	9,038
Accounts receivable from Healios, billed and unbilled			664				716
Prepaid expenses, deposits and other			1,225				3,781
Operating right-of-use assets, net			38				7,846
Property and equipment, net			4,644				4,214
Deposits and other			2,114				2,136
Total assets		$	10,477			$	27,731
Liabilities and stockholders’ equity
Accounts payable, accrued expenses and other current liabilities		$	10,805			$	37,164
Deferred revenue - Healios			7,862				8,685
Operating lease liabilities			8,390				534
Warrant liability			—				5,199
Advance from Healios			5,199				—
Note Payable			15,640				—
Total stockholders' equity			(37,419	)			(23,851	)
Total liabilities and stockholders' equity		$	10,477			$	27,731

Note: The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.

Athersys, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In Thousands, Except Per Share Amounts)
		Three months ended June 30,
			2023				2022
Revenues
Contract revenue from Healios		$	49			$	2,316
Total revenues			49				2,316
Costs and expenses
Research and development			10,649				20,794
General and administrative			2,345				5,162
Depreciation			43				618
Total costs and expenses			13,037				26,574
Loss from operations			(12,988	)			(24,258	)
Other income, net			64				610
Net loss and comprehensive loss		$	(12,924	)		$	(23,648	)
Net loss per share, basic and diluted		$	(0.62	)		$	(2.28	)
Weighted average shares outstanding, basic and diluted			20,700				10,383

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230816907178/en/

Athersys

Ellen Gurley

Manager of Corporate Communications and Investor Relations

ir@athersys.com

LHA Investor Relations

Tirth T. Patel

212-201-6614

tpatel@lhai.com

Source: Athersys, Inc.

FAQ

What is the stock symbol for Athersys, Inc.?

The stock symbol for Athersys, Inc. is ATHX.

What were the financial results for Q2 2023?

Athersys, Inc. reported $48.8K in revenue, $10.6M in research and development expenses, $2.3M in general and administrative expenses, and a net loss of $(12.9)M.

How did the financial results compare to Q2 2022?

Revenue decreased from $2.3M in Q2 2022 to $48.8K in Q2 2023. Research and development expenses decreased from $20.8M to $10.6M, and general and administrative expenses decreased from $5.2M to $2.3M. The net loss also decreased from $(23.6)M to $(12.9)M.

What is the cash and cash equivalents as of June 30, 2023?

The cash and cash equivalents for Athersys, Inc. as of June 30, 2023, were $1.8M.